Two medications, different approaches
While both medications belong to the incretin therapy class, they work through different mechanisms.
A factual comparison based on published clinical research. Semaglutide and tirzepatide are the two most widely prescribed GLP-1 medications today. This page compares them using data from published clinical trials so you can have an informed conversation with your healthcare provider.
While both medications belong to the incretin therapy class, they work through different mechanisms.
Data sourced from published clinical trials and FDA-approved labeling.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GLP-1/GIP receptor agonist |
| Mechanism | Mimics GLP-1 hormone | Mimics both GLP-1 and GIP hormones |
| Brand names (weight loss) | Wegovy | Zepbound |
| Brand names (diabetes) | Ozempic, Rybelsus | Mounjaro |
| Administration | Weekly injection or daily oral | Weekly injection |
| Avg weight loss (trials) | ~15% body weight (STEP 1) | ~21% body weight (SURMOUNT-1) |
| Key clinical trial | STEP program | SURMOUNT program |
| FDA approval (weight) | 2021 (Wegovy) | 2023 (Zepbound) |
| Manufacturer | Novo Nordisk | Eli Lilly |
Both medications have been studied in large, multi-center, randomized controlled trials. Here is a summary of published findings.
Three fundamental ways these medications differ.
Only your healthcare provider can determine which medication is appropriate for your individual health needs. This comparison presents published clinical data to help inform your conversation with your doctor.
Factors your doctor may consider include your medical history, existing conditions, insurance coverage, and treatment goals. The "best" medication is the one that is most appropriate for your specific situation.
Whether you're on semaglutide or tirzepatide, Dose AI tracks your injections, symptoms, weight, and nutrition in one place.
Clinical trials show higher average weight loss with tirzepatide, but individual responses vary significantly. These trials were conducted separately with different study populations, so direct comparison has limitations. Your doctor can help determine the best option based on your individual health profile.
No. They are different medications with different mechanisms of action. Semaglutide targets GLP-1 receptors only, while tirzepatide targets both GLP-1 and GIP receptors. They are made by different manufacturers and sold under different brand names.
Medication changes should always be discussed with your prescribing healthcare provider. They can evaluate whether a switch is appropriate for your situation and manage the transition safely.
They share common gastrointestinal side effects such as nausea, vomiting, and diarrhea, but differ in specifics and frequency. Review the complete published safety data for each medication and discuss any concerns with your doctor.
Costs vary significantly by brand name, insurance coverage, pharmacy, and available manufacturer savings programs. The list price is not what most patients pay. Check with your insurance provider and pharmacy for the most accurate pricing for your situation.
Yes. Dose AI works with any GLP-1 medication, including both semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). The app tracks injections, symptoms, weight, nutrition, and more regardless of which medication you take.
Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making any decisions about your health or medications.